DBI's market is large and growing. Currently, Parkinson's disease affects more than 6.3 million people globally, with 60,000 new cases diagnosed annually in the United States.
Deep brain stimulation (DBS) devices use implantable pulse generators (IPGs) and leads, targeting specific areas of the brain to reduce the motor symptoms of Parkinson's disease including tremor, slowness of movement and rigidity. These devices are implanted in Parkinson's patients whose condition is not adequately managed by the oral pharmaceuticals that are intended to increase dopamine concentration in the brain. Once implanted, conventional deep brain stimulation (DBS) systems deliver continuous stimulation to targeted nuclei in the brain.
There have been approximately 80,000 deep brain stimulation surgeries completed since 1997 resulting in an estimated $275M in annual device-related revenues. However, there are limitations related to conventional DBS technology that DBI's TOPS™ is intended to address.
DBI's Temporally Optimized Patterned Stimulation (TOPS) technology is designed to enable development of deep brain stimulation systems with significantly decreased power consumption to: